MSLN and metastatic neoplasm: Moreover, the prognostic value of MSLN expression, its expression profiles in rare and aggressive histological types, such as gastric-type adenocarcinoma (GAS) and neuroendocrine carcinoma (NEC), and differences in its expression levels between primary and metastatic tumours remain unclear.